5 January 2020 - Daiichi Sankyo and the University of Tokyo are collaboratively developing teserpaturev, which has received SAKIGAKE designation and orphan drug designation in Japan.
Daiichi Sankyo today announced it has submitted a new drug application to Japan’s Ministry of Health, Labour and Welfare for teserpaturev (G47∆), an oncolytic virus, for the treatment of patients with malignant glioma.
The Japan new drug application submission, which took place on 28 December 2020, is based on results of a single-arm phase 2 clinical trial conducted by Dr. Todo at the University of Tokyo in patients with residual or recurrent glioblastoma tumours, which met its primary outcome for one year survival rate.